Thermo Fisher Launches In-Air SARS-CoV-2 Surveillance Solution

Thermo Fisher Scientific Inc. (Waltham, MA, USA) has launched the Thermo Scientific AerosolSense Sampler, a new surveillance solution designed to deliver fast and highly reliable insight into the presence of in-air pathogens, including SARS-CoV-2.

The AerosolSense Sampler is an in-air pathogen surveillance solution, which collects representative aerosol samples of ambient air and traps in-air pathogens on a collection substrate. The sample can be readily analyzed through subsequent laboratory testing using polymerase chain reaction (PCR) methodology. Confirming the presence of pathogens like SARS-CoV-2 in a space during a known time interval enables decision makers in hospitals and other indoor facilities to take actions to protect their employees and provide the public with confidence. Thermo Fisher has designed the AerosolSense Sampler to capture a wide variety of in-air pathogens and has specifically validated it for the SARS-CoV-2 pathogen.


"Such factors as emerging variants, semi-vaccinated populations and varying levels of compliance with COVID-19 personal safety protocols, continue to pose risks to a society looking to return to life as it was before the pandemic," said Mark Stevenson, executive vice president and chief operating officer of Thermo Fisher Scientific. "It is important that easy-to-use, highly reliable solutions be available to allow hospitals, nursing homes, schools, businesses and government institutions to identify the presence of in-air pathogens quickly, so safety protocols can be put into action, validated, or strengthened."